Abstract: The development of novel molecular cancer imaging agents has considerably advanced in recent years. Numerous cancer imaging agents have demonstrated remarkable potential for aiding the diagnosis, staging, and treatment planning at the preclinical stage, which in turn has led to a number of agents being approved for human trials. Pancreatic ductal adenocarcinoma is currently the most deadly common carcinoma with an overall 5-year survival rate of about 6%. As detection technologies progress, the need for molecular imaging tools that will allow the diagnosis at an early stage will be crucial to improving patient outcomes. In this review, we will highlight agents that illuminate various cell populations that comprise the tumor: epithelial, endothelial, and stromal tumor cells.
T he development of novel molecular imaging agents has advanced at an exceptional rate in recent years. Numerous imaging agents have demonstrated remarkable potential for aiding the diagnosis, staging, and treatment planning at the preclinical stage, which in turn has led to a number of agents being approved for human trials. The understanding of the biology of many cancers, including the role of the tumor microenvironment, has expanded rapidly in the past decade, and this is beginning to lead to rapid advances in the development of molecular imaging agents for various cancers.
Pancreatic ductal adenocarcinoma (PDAC) is currently the most deadly common carcinoma with an overall 5-year survival rate of about 6%. For the 25% of patients who qualify for surgical resection, the only cure for the disease, the 5-year survival rate is still only 20%. [1] [2] [3] The dire prognosis for PDAC patients is largely due to the inadequacy of the tools and treatments available for combating the disease, and recent advances in chemotherapy for PDAC patients have only marginally increased survival. [4] [5] [6] [7] [8] [9] The complications associated with the diagnosis, staging, and treatment of PDAC could potentially be alleviated by the intelligent design and implementation of novel molecular imaging techniques, which could in turn improve the outcomes for PDAC patients.
Currently, because of the low incidence of pancreatic cancer and the limitations of current technologies, it is not feasible or cost-effective to screen the general population for cases of sporadic cancer. However, there are patient populations with a high heightened risk of developing PDAC that are currently being screened, and as our understanding of PDAC-related serum biomarkers increases, it will become easier to develop more efficient screens to identify at-risk individuals within the general population. As these technologies progress, the need for complementary molecular imaging tools that will allow the diagnosis at an early stage will be crucial to improving patient outcomes. In the following sections, we will highlight agents that illuminate various cell populations that comprise the tumor: epithelial, endothelial, and stromal tumor cells.
Tumor Endothelial Cells
Ultrasound is an inexpensive, portable, noninvasive, and widely available imaging modality that could more easily be adapted to widespread screening of at-risk patients when compared with other functional imaging techniques such as magnetic resonance imaging and computed tomography (CT). With that in mind, researchers are currently working to develop techniques that take advantage of ultrasound technology and molecular targeting to generate molecular imaging tools for PDAC. Microbubbles are small, gas-filled microspheres with specific acoustic properties that make them a useful contrast agent for ultrasound imaging. Because of their size, microbubbles are restricted to the vascular compartment, so they can be used to identify areas of inflammation, atherosclerotic plaques, thrombi, and other cardiovascular pathologies. By coupling a targeting agent such as antibodies or peptides, cancer-specific binding of the microbubbles to the tumor endothelial has been achieved with incredible results.
In 1 such study, Korpanty et al 20 used antibodies targeting protein antigens that are highly expressed in pancreatic tumors, such as vascular endothelial growth factor receptor 2 (VEGFR2), in orthotopic murine models of PDAC. Vascular endothelial growth factor receptor 2 is a major contributor to tumor angiogenesis and is overexpressed on tumor endothelial cells of angiogenic vessels in pancreatic cancer [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] and in almost all cancers. In the study, Korpanty et al 20 demonstrated the effectiveness of using molecularly targeted microbubbles to monitor angiogenesis and changes in the vasculature in response to anticancer agents. More recently, Deshpande et al 21 conjugated an anti-VEGFR2 antibody to microbubbles. It was shown that contrast-enhanced ultrasound could be used to monitor the expression levels of VEGFR2 in subcutaneous xenografts, suggesting the potential for stratifying patients as well as personalizing therapy.
Thymocyte differentiation antigen 1 (Thy1) was recently identified as a vascular marker in a proteomic screen comparing human PDAC to chronic pancreatitis and normal pancreas. 22 Foygel et al 22 demonstrated that Thy1-targeted microbubbles were able to accurately differentiate PDAC in both xenograft and genetically engineered mouse models. The results were significant when compared with pancreas imaging performed on normal animals or animals with chronic pancreatitis, a risk factor for pancreatic cancer (Fig. 1) . Furthermore, the microbubble-enhanced ultrasound imaging was able to identify animals with pancreatic intraepithelial neoplasia 3 (PanIN-3), an advanced precursor lesion that if identified and removed could prevent pancreatic cancer.
Tumor Epithelial Cells
Claudin-4, a transmembrane protein that is a component of tight junctions in epithelial cells, is up-regulated in PDAC and late-stage PanIN lesions. In addition to pancreatic cancer, claudin-4 is a potential target in chemotherapy-resistant ovarian cancer and other highly aggressive human epithelial tumors including breast and prostate cancer, making it attractive as a molecular imaging target. 23, 24 Moreover, targeting claudin-4 for therapy of PDAC was the subject of a recent review by Kojima et al, 25 and a number of studies describing claudin-4 as a target for molecular imaging have recently been reported. Neesse et al 26 assessed the ability of a naturally occurring peptide ligand for claudin-4 to detect tumors that overexpress claudin-4. It was shown that C-CPE (carboxyl-terminal portion of Clostridium perfringens enterotoxin) binds with high affinity to claudin-4, even when the aminoterminal portion (enterotoxin) of the protein is removed. A Cy5.5-coupled C-CPE was developed for imaging claudin-4-positive lesions in murine models of PDAC with very promising results. In addition, Foss et al 27 evaluated a 125 I-radiolabeled anticlaudin-4 tracer in an experimental murine xenograft model. An excellent tumor-to-muscle uptake ratio of more than 6:1 was obtained 4 days after injection by ex vivo biodistribution analysis in a Panc1 xenograft model. Although the pharmacokinetic characteristics of the recently reported agents need improvement, anticlaudin-4 targeting vectors have shown immense promise as potential diagnostic imaging agents for PDAC.
Plectin-1 is a cytosolic scaffolding molecule and member of the cytolinkers family. Because of its mislocalization to the extracellular surface of PDAC and PanIN-3 lesions, plectin-1 has been identified as a relevant target for molecular imaging of pancreatic cancer. 28, 29 Expression of plectin-1 in high-grade PanIN and PDAC is significantly amplified compared with normal pancreas, chronic pancreatitis, and low-grade PanIN with 87% sensitivity and 98% specificity. Pancreatic ductal adenocarcinoma was identified with 100% sensitivity and specificity. 30 Plectin-1-targeted peptide (PTP), a promising molecular imaging agent for the early diagnosis of PDAC, was originally discovered by phage display screening and has been modified to include DOTA for 111 Inradiolabeling and evaluated in orthotopic L3.6pl and Panc1 mice. 31 In both models, imaging illuminated pancreatic tumors (Fig. 2) and metastases. 
Stromal Cells
Studying the tumor biology has revealed that the tumor microenvironment or stroma has an important role in tumor biology and also furnishes a wealth of targets for molecular imaging. While the PanIN-3 lesions, PDAC precursor, 32 have relatively low epithelial cell counts from a quantitative standpoint, the surrounding cancer-associated fibroblasts (CAFs) are much greater in quantity and represent a potential route for early detection of pancreatic cancer. For every epithelial cell, there are an estimated 10 to 100 times or more adjacent CAFs, distinctly abnormal.
Cathepsin E (cath E) is an aspartic protease that is not expressed in healthy pancreatic tissue but is highly expressed in PDACs and PanIN lesions. Cruz-Monserrate et al 33 engineered a cath E-activatable imaging probe labeled with Cy5.5. The cath E-activatable imaging probe consisted of an inert polyethylene glycol-protected grafted D-polylysine copolymeric template and multiple copies of a Cy5.5-labeled cath E-selective peptide In-tPTP and imaged via single-photon emission CT (SPECT)/CT 4 hours after injection. Note the accumulation of tPTP in PDAC, allowing the in vivo imaging of tumor in the pancreas and in peritoneal metastases. Coronal (left) and axial (right) SPECT/CT slices through the tumor are presented. T indicates tumor; K, kidney; M, peritoneal metastasis. C, After SPECT/CT imaging, animals were killed, organs harvested, and gamma counts assessed. Null data are from both nu/nu and FVB/NJ animals that were injected in the pancreas with saline. D, Histology. Animals that had orthotopically implanted tumors or null animals were killed, and pancreas and regions of visible peritoneal metastases were removed, embedded, sectioned, and stained with hematoxylin-eosin (20 images). PT indicates primary tumor; PM, peritoneal metastasis.
sequence. Because of the close proximity of the attached fluorochromes in the imaging probe, the probe remains optically quenched, until the cath E enzyme acts on the peptide linkers and releases the fluorescent reporters. The authors demonstrated that the cath E-activatable imaging probe selectively bound and was able to allow the visualization of PanIN and PDAC lesions. Alas, because of the limitations of optical imaging, this type of contrast agent would not be applicable to noninvasive imaging but could be exploited in fluorescent endoscopic imaging or during surgery.
Secreted protein acidic and rich in cysteine (SPARC) is a protein that is present in aggressive cancers including prostate, breast, lung, ovarian, and pancreatic. A high level of SPARC expression correlates with a poor prognosis. Secreted by stromal cells such Zr-5B1 at 48 hours after injection was 30.7% ± 6.6% ID/g (P < 0.001). Tumor-to-muscle ratios (T/M, C, right) determined for 89 Zr-5B1 were 6.2 ± 2.3 (2 hours), 11.0 ± 1.9 (24 hours), 20.9 ± 3.9 (48 hours), 21.2 ± 4.7 (96 hours), and 22.7 ± 5.9 (120 hours), whereas 18 FDG provided a 3.5 ± 1.1 T/M contrast ratio (P < 0.001). The coregistration of 18 FDG PET and CT (left) and planar sections of 18 FDG PET only (right) displayed minimal tumor detection of the tracer with a high uptake in highly metabolic tissues (i.e., heart) (D). Acquired as CAFs, SPARC plays an important role in cell-matrix adhesion. 34, 35 Secreted protein acidic and rich in cysteine-targeted peptides conjugated to fluorescent nanoparticles were able to delineate lung and bone metastases of prostate cancer. 36 Given the importance of SPARC to pancreatic cancer stroma, SPARC represents a target that may be useful for pancreatic cancer imaging.
Circulating Tumor Biomarkers
The diagnosis of PDAC is often based partially on the detection of elevated levels of circulating CA-19-9 (sialyl Lewis a ) in sera. 37, 38 CA-19-9 is a ligand for epithelial leukocyte adhesion molecules, and its overexpression is a key event in invasion and metastasis of many tumors, including PDAC tumors. 39 However, the use of assays to detect circulating CA-19-9 antigen for the diagnosis of PDAC has significant shortcomings that limit its utility to the screening and identification of potentially at-risk patients. [7] [8] [9] While screening efforts to identify novel biomarkers is a promising course of action that led to the identification promising biomarkers such as plectin-1 and claudin-4, it also stands to reason that simply changing the manner in which a flawed biomarker is assayed could rescue its diagnostic utility. In the case of CA-19-9, recent studies have endeavored to develop a tool that can discriminate the tissue site(s) of circulating biomarker production and clearly distinguish benign from malignant disease.
Toward that end, a number of anti-CA-19-9 positron emission tomography (PET) tracers have recently been reported, several of which are promising. The fully human mAb 5B1, which potently binds an extracellular epitope of CA-19-9, was developed as a platform for immuno-PET imaging of PDAC.
40 5B1 was conjugated to desferrioxamine and radiolabeled with 89 Zr for PET imaging. Imaging studies showed excellent uptake and clearly delineated tumor tissue in numerous murine models of PDAC, outperforming fluorodeoxyglucose ( 18 FDG) in a comparative study (Fig. 3) . 41 One major concern that arose in the initial studies with 5B1 was the potential for circulating CA-19-9 to diminish the usefulness of 5B1. However, initial studies indicated that 5B1 was able to delineate the tumors in the context of shed antigen. In addition to 5B1, a number anti-CA-19-9 antibody fragments have recently been reported. [42] [43] [44] Antibody fragments are expected to increase tumor penetration and reduce the lag time between injection and imaging, providing a benefit to patients in terms of time spent in the clinic and exposure to radiation. While initial results with many of the anti-CA-19-9 tracers are promising, murine models lack any endogenous expression of CA-19-9, and until more biologically relevant murine models are developed or clinical data in humans become available, the utility of these tracers will remain uncertain.
CONCLUSION
While molecular imaging has a history of success with many common cancers, including breast and prostate cancers, to date, it has not been as effectively applied to pancreatic cancer. There are a number of reasons for this discrepancy, but progress has accelerated in recent years, providing hope that molecular imaging technology will soon be as widely applicable to the treatment of pancreatic cancer. With pancreatic cancer projected to become the second-leading cause of cancer deaths in the United States by the year 2020, these advances cannot come fast enough. There are currently numerous clinical trials ongoing at cancer centers around the world aimed at developing an arsenal of molecular imaging technologies that will improve patient outcomes in ways that conventional imaging technologies such as magnetic resonance imaging and CT cannot. Molecular imaging has the benefit of being able to differentiating between tumor, healthy pancreas, or pancreatitis on a molecular level, while also providing anatomical information about tumors. Furthermore, molecular imaging may also be used to quantify levels of biomarkers in tumors, which has implications in the emerging field of personalized medicine.
